Showing results (51-60 of 244) with videos related to
Sort By:
Pageof 25
Clinical Pharmacology and Therapeutics|December 29, 1999
Ticlopidine inhibits phenytoin clearanceS Donahue, D A Flockhart, D R AbernethyLife Sciences|January 1, 1996
Endothelin-1 induces an increase in total protein synthesis and expression of the smooth muscle alpha-actin gene in vascular smooth muscle cellsN S Andrawis, E Wang, D R AbernethyInternational Journal of Clinical Pharmacology, Therapy, and Toxicology|February 1, 1983
Kinetics of low-dose intravenous antipyrine: use of liquid chromatographyD J Greenblatt, D R Abernethy, M DivollClinical Pharmacology and Therapeutics|December 1, 1992
Endothelin-I-mediated vasoconstriction: specific blockade by verapamilN S Andrawis, J Gilligan, D R AbernethyClinical Pharmacology and Therapeutics|July 1, 1990
Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to dispositionD R Abernethy, J Gutkowska, L M WinterbottomClinical Pharmacology and Therapeutics|September 1, 1995
Local angiotensin-converting enzyme inhibition blunts endothelin-1-induced increase in forearm vascular resistanceD R Abernethy, N Laurie, N S AndrawisJournal of Clinical Pharmacology|August 1, 1983
Is volume of distribution at steady state a meaningful kinetic variable?D J Greenblatt, D R Abernethy, M DivollJournal of Cardiovascular Pharmacology|January 1, 1988
Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamicsD R Abernethy, J Gutkowska, M D LambertThe Journal of Pharmacology and Experimental Therapeutics|June 1, 1992
Calcium antagonists block angiotensin II-mediated vasoconstriction in humans: comparison with their effect on phenylephrine-induced vasoconstrictionN S Andrawis, N Craft, D R AbernethyJournal of Clinical Pharmacology|August 1, 1995
Moexipril in the treatment of mild to moderate essential hypertension: comparison with sustained-release verapamilD R Abernethy, A A Fox, M StimpelPageof 25